
Innogen will receive $38 million upfront and near-term for rights to its ultra-long-acting GLP-1 efsubaglutide alfa across four emerging regions.
Important IP contractual provisions should be included when working with CMOs.
Biotechnology and pharmaceutical companies often engage contract CMOs to assist with the development of their drugs. This type of arrangement naturally involves the development of intellectual property (IP), so it is important for both the CMO and the sponsor to identify pre-existing intellectual property and also define how rights to new IP will be allocated, protected, and enforced by and between the companies.
over 11 years ago
QRM Tools for Contract Biomanufacturingover 11 years ago
Fill/Finish Trendsover 11 years ago
Biopharma Advances Demand Specialized Expertiseover 11 years ago
Taking a “Development-by-Design” Approach to Cell Therapies






